211 related articles for article (PubMed ID: 17508272)
1. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
Endoh M
Cardiovasc Drugs Ther; 2007 Jun; 21(3):135-9. PubMed ID: 17508272
[No Abstract] [Full Text] [Related]
2. [Levosimendan].
Michels G; Herzig S; Hoppe UC
Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
[No Abstract] [Full Text] [Related]
3. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
Duncker DJ; Verdouw PD
Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
[No Abstract] [Full Text] [Related]
4. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Stehlik J; Movsesian MA
Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
[TBL] [Abstract][Full Text] [Related]
5. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
Kass DA
Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
[No Abstract] [Full Text] [Related]
6. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
7. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
Sato N
Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364
[No Abstract] [Full Text] [Related]
8. [How to use PDE III inhibitors].
Goto Y
Nihon Rinsho; 2007 May; 65 Suppl 5():49-56. PubMed ID: 17571365
[No Abstract] [Full Text] [Related]
9. Phosphodiesterase 4 regulation of cyclic AMP in pulmonary remodelling: potential roles for isoform selective inhibitors.
Shepherd MC
Pulm Pharmacol Ther; 2006; 19(1):24-31. PubMed ID: 16046159
[No Abstract] [Full Text] [Related]
10. [Combination therapy with PDE III inhibitor for heart failure].
Watanabe H; Kajimoto K; Kawana M
Nihon Rinsho; 2007 May; 65 Suppl 5():134-9. PubMed ID: 17571377
[No Abstract] [Full Text] [Related]
11. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
[TBL] [Abstract][Full Text] [Related]
12. Interactions between inotropic drugs.
Ducart A
Acta Anaesthesiol Belg; 2001; 52(4):377-84. PubMed ID: 11799570
[No Abstract] [Full Text] [Related]
13. Calcium sensitizers, a new class of inodilators.
Kwak YL
Int Anesthesiol Clin; 2005; 43(2):115-33. PubMed ID: 15795567
[No Abstract] [Full Text] [Related]
14. Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.
Okruhlicová L; Tribulová N; Eckly A; Lugnier C; Slezák J
Histochem J; 1996 Mar; 28(3):165-72. PubMed ID: 8735283
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of novel cardiotonic agents.
Endoh M
Expert Opin Investig Drugs; 2003 May; 12(5):735-50. PubMed ID: 12720486
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
18. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.
Movsesian MA
Expert Opin Investig Drugs; 2000 May; 9(5):963-73. PubMed ID: 11060720
[TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
Manganiello V
Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
[No Abstract] [Full Text] [Related]
20. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
